{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:47:03Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 18.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09502-56bf-73c1-bc52-b093459c257f\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: fluspirilene\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 re", "usd": 0.0, "recall": true }, "codex": { "seconds": 69.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09502-56d0-7b01-bdef-9d4edb32a792\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: fluspirilene\nRegistry id: vr.tr.fluspirilene\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:48:58+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q408300", "registryId": "vr.tr.fluspirilene", "name": "fluspirilene", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q408300/", "model": { "registry_id": "vr.tr.fluspirilene", "name": "fluspirilene", "purpose": "Enable an agent to identify fluspirilene, assess the quality and state of a material containing it, and determine whether evidence supports a proposed handling, research or pharmaceutical use.", "definition": "Fluspirilene is a synthetic diphenylbutylpiperidine antipsychotic substance whose dopamine D2 receptor antagonism supports its use in long-acting intramuscular preparations for treating schizophrenia.", "scope_statement": "This model owns fluspirilene as the chemical substance registered as vr.tr.fluspirilene in PHY / PHY.MAT, including molecular identity, material quality, physical state, biological activity evidence and substance-level handling constraints.", "in_scope": [ "Molecular structure and identifiers distinguishing fluspirilene from related antipsychotics", "Composition, assay, impurities and grade of fluspirilene material", "Solid form, particle properties, solubility and stability under recorded conditions", "Experiment-specific pharmacological activity and its evidential limits", "Substance-level hazards, storage requirements and jurisdiction-specific identity" ], "out_of_scope": [ "Finished injectable medicines, their excipients, packaging and administration devices", "Patient diagnosis, prescribing, dosing and treatment monitoring", "Manufacturing routes and production equipment", "Independent models of metabolites, degradation products and related antipsychotics", "Clinical trials and regulatory applications as managed activities" ], "distinguishing_features": [ "Match the molecular structure to PubChem CID 3396 and InChIKey QOYHHIBFXOOADH-UHFFFAOYSA-N; a similar drug name or therapeutic class is insufficient.", "Require the combination of a bis(4-fluorophenyl)butyl substituent and a phenyl-substituted triazaspirodecanone framework, rather than identifying any diphenylbutylpiperidine antipsychotic as fluspirilene.", "Check consistency with molecular formula C29H31F2N3O and CAS 1841-19-6, while using analytical evidence to establish the identity of an actual sample.", "Distinguish fluspirilene substance from products called Imap or Redeptin, which require their own composition and authorization records.", "Distinguish the parent substance from salts, solvates, metabolites and degradation products through explicit composition and structure records." ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "CAS 1841-19-6; PubChem CID 3396; EC 217-418-6; UNII C5QA4GLR9M", "why_it_matters": "Connects substance records across suppliers and registries; identifiers are reported by [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fluspirilene)." }, { "name": "Molecular composition", "kind": "category", "unit_or_values": "C29H31F2N3O; molecular weight approximately 475.6 g/mol", "why_it_matters": "Supports identity checks and mass-to-amount conversions for the specified molecular form." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% w/w or validated equivalent; as-is, dried or solvent-free basis", "why_it_matters": "Separates actual fluspirilene content from chromatographic area percentage and prevents incorrect concentration calculations." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in % or mg/kg, with method and detection limits", "why_it_matters": "Supports grade-specific acceptance and interpretation of biological experiments." }, { "name": "Solid form and particle distribution", "kind": "state", "unit_or_values": "Observed crystalline or amorphous state; identified phase; D10, D50 and D90 in µm", "why_it_matters": "Allows assessment of dissolution and suspension behavior without assuming all lots behave alike." }, { "name": "Solubility under specified conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L, with solvent, pH, temperature and equilibration method", "why_it_matters": "Determines whether preparation of a solution is supported and whether precipitation could affect an assay." }, { "name": "Thermal behavior", "kind": "measurement", "unit_or_values": "Melting or decomposition interval in °C; method, pressure and sample form", "why_it_matters": "Supports material characterization without confusing decomposition with a usable boiling point." }, { "name": "Target activity evidence", "kind": "relation", "unit_or_values": "Target, species, assay, effect type and Ki, Kd, IC50 or EC50 with units", "why_it_matters": "Keeps measured binding and functional effects distinct from clinical efficacy." }, { "name": "Material disposition", "kind": "state", "unit_or_values": "Unassessed, quarantined, accepted for specified use, rejected or expired", "why_it_matters": "Connects evidence and grade to a concrete decision about a particular lot." } ], "affordances": [ "Resolve a named or coded material to fluspirilene using structural identifiers and analytical records.", "Assess whether a lot meets an explicitly selected research or pharmaceutical material specification.", "Calculate fluspirilene content and preparation concentrations using assay and molecular-form corrections.", "Evaluate whether measured solubility, solid form and particle properties support a proposed preparation.", "Compare biological activity reports while preserving target, species and assay differences.", "Assign evidence-supported handling and storage requirements or hold the material pending missing evidence." ], "agent_conduct": { "may": [ "Explain fluspirilene's class and use as a long-acting antipsychotic from authoritative sources.", "Help a care team keep records of scheduled injections that they have authorised." ], "must_not": [ "Recommend, dose or administer it without a prescriber's decision.", "Assist in giving it to a person covertly or without lawful authority.", "Disclose a person's psychiatric diagnosis or treatment without consent or legal basis.", "Dismiss movement disorders or other side effects a patient reports." ], "requires_human": [ "Any decision on treatment of a person, especially under mental health law." ] }, "ethics": { "considerations": [ "Long-acting antipsychotics are sometimes given under compulsion; consent and rights must be respected.", "Mental illness carries stigma, so treatment information is sensitive." ], "affected_parties": [ "Patients with schizophrenia", "Families and carers", "Clinicians" ] }, "owners": { "steward": "The marketing authorisation holder where it is licensed; the prescriber answers for each patient's use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Supplied as an injectable suspension for intramuscular use; identity must be confirmed by label and pharmacy records." ], "failure_modes_and_hazards": [ "Can cause movement disorders, including late-onset involuntary movements.", "Rare but serious reactions such as neuroleptic malignant syndrome are possible.", "Long action means side effects persist after the injection." ], "what_it_is_for": [ "Fluspirilene is used as an antipsychotic substance in long-acting intramuscular pharmaceutical preparations.", "It is also encountered in pharmaceutical analysis and receptor pharmacology research, where substance identity and formulation must be distinguished." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns fluspirilene code N05AG01." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q408300: fluspirilene", "url": "https://www.wikidata.org/wiki/Q408300", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Fluspirilene", "url": "https://en.wikipedia.org/wiki/Fluspirilene", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "fluspirilene-identity", "name": "Fluspirilene identity and boundaries", "description": "Establishes the exact chemical entity and separates it from named medicines and neighboring substances.", "rationale": "Shared pharmacological classes and product synonyms cannot establish molecular identity.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Connects structure and identifiers to sample-level identity evidence.", "findings": [ { "id": "parent-structure", "name": "Parent structure match", "description": "The identity anchor is the structure recorded for fluspirilene in [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fluspirilene); sample recognition additionally requires suitable analytical evidence.", "questions": [ { "text": "Does the supplied structure match fluspirilene's fluorinated aromatic substituents and triazaspirodecanone framework?", "kind": "definition", "id": "parent-structure-q01" }, { "text": "Which reference material and analytical results establish that this sample contains fluspirilene?", "kind": "provenance", "id": "parent-structure-q02" } ] } ] }, { "id": "substance-product-boundary", "name": "Substance and product boundary", "description": "Prevents product names or modified chemical forms from silently replacing the parent substance.", "findings": [ { "id": "form-and-name-resolution", "name": "Form and name resolution", "description": "A product label, salt designation or solvate claim must be resolved explicitly before assigning parent-substance properties.", "questions": [ { "text": "Does the record describe fluspirilene itself, a specified chemical form or a formulated medicine containing it?", "kind": "boundary", "id": "form-and-name-resolution-q01" }, { "text": "What evidence connects a supplier synonym or product name to the registered substance?", "kind": "provenance", "id": "form-and-name-resolution-q02" } ] } ] } ] }, { "id": "fluspirilene-material-quality", "name": "Fluspirilene material quality", "description": "Establishes the composition and fitness of an identifiable lot.", "rationale": "Correct identity alone does not establish usable concentration or suitability for pharmaceutical work.", "layers": [ { "id": "content-and-contaminants", "name": "Content and contaminants", "description": "Records fluspirilene content separately from impurities, water and residual solvents.", "findings": [ { "id": "assay-basis", "name": "Interpretable assay", "description": "Assay values need a measurement method and reporting basis before they can support quantity calculations.", "questions": [ { "text": "What is the measured fluspirilene mass fraction, and is it reported as-is or after correction for water and solvents?", "kind": "measurement", "id": "assay-basis-q01" }, { "text": "Which related substances, residual solvents and other contaminants were measured, and at what limits?", "kind": "measurement", "id": "assay-basis-q02" } ] } ] }, { "id": "grade-and-disposition", "name": "Grade and disposition", "description": "Connects lot documentation to a specific intended use.", "findings": [ { "id": "use-specific-acceptance", "name": "Use-specific acceptance", "description": "Research grade, reference-standard status and pharmaceutical suitability require separate supporting evidence.", "questions": [ { "text": "Which specification, certificate and lot history substantiate the claimed fluspirilene grade?", "kind": "provenance", "id": "use-specific-acceptance-q01" }, { "text": "Should this lot be accepted for the proposed use, tested further or quarantined?", "kind": "action", "id": "use-specific-acceptance-q02" } ] } ] } ] }, { "id": "fluspirilene-physical-behavior", "name": "Fluspirilene physical behavior", "description": "Characterizes the material properties relevant to dissolution, suspension and storage.", "rationale": "The substance's association with long-acting injectable medicines makes physical-form evidence particularly relevant, while finished-product performance remains outside this model.", "layers": [ { "id": "solid-and-thermal-state", "name": "Solid and thermal state", "description": "Records observed phase, particle properties and thermal transitions.", "findings": [ { "id": "characterized-solid", "name": "Characterized solid material", "description": "Solid form and thermal properties are measurements to establish for the material, not constants to infer from its drug name.", "questions": [ { "text": "What diffraction, thermal or other evidence identifies the fluspirilene solid form and any solvation?", "kind": "measurement", "id": "characterized-solid-q01" }, { "text": "What particle-size distribution and melting or decomposition behavior were measured under stated conditions?", "kind": "measurement", "id": "characterized-solid-q02" } ] } ] }, { "id": "solution-and-storage-behavior", "name": "Solution and storage behavior", "description": "Connects solvent conditions and storage history to usable material state.", "findings": [ { "id": "preparation-stability", "name": "Preparation and stability evidence", "description": "Preparation decisions require measured solubility and stability for the actual solvent system and intended duration.", "questions": [ { "text": "What fluspirilene concentration remains dissolved at the specified solvent composition, pH and temperature?", "kind": "measurement", "id": "preparation-stability-q01" }, { "text": "Which storage or preparation conditions have evidence for maintaining assay and limiting degradation or precipitation?", "kind": "action", "id": "preparation-stability-q02" } ] } ] } ] }, { "id": "fluspirilene-biological-activity", "name": "Fluspirilene biological activity", "description": "Organizes evidence for antipsychotic pharmacology and experimentally observed target interactions.", "rationale": "An agent must distinguish established pharmacological context from assay-specific effects and unproven therapeutic applications.", "layers": [ { "id": "pharmacological-context", "name": "Pharmacological context", "description": "Connects the substance to its documented drug class without assigning patient-level instructions.", "findings": [ { "id": "antipsychotic-role", "name": "Documented antipsychotic role", "description": "The [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=85) describes fluspirilene as a long-acting typical antipsychotic.", "questions": [ { "text": "Which primary experiments support the recorded dopamine-receptor interactions, with what species and assay conditions?", "kind": "provenance", "id": "antipsychotic-role-q01" }, { "text": "Which duration-of-action claims depend on an injectable formulation rather than the isolated substance?", "kind": "boundary", "id": "antipsychotic-role-q02" } ] } ] }, { "id": "experimental-target-effects", "name": "Experimental target effects", "description": "Preserves the context and limitations of additional biological findings.", "findings": [ { "id": "calcium-channel-evidence", "name": "Calcium-channel interaction evidence", "description": "A [primary study](https://pubmed.ncbi.nlm.nih.gov/2538426/) reports high-affinity binding in porcine cardiac sarcolemmal membranes and evidence of L-type calcium-channel inhibition; this does not establish a separate clinical indication.", "questions": [ { "text": "Was the recorded result binding, functional inhibition or a downstream cellular response, and at what concentration?", "kind": "measurement", "id": "calcium-channel-evidence-q01" }, { "text": "What evidence supports extrapolation beyond the tested preparation, species and exposure conditions?", "kind": "boundary", "id": "calcium-channel-evidence-q02" } ] } ] } ] }, { "id": "fluspirilene-handling-constraints", "name": "Fluspirilene handling and regulatory constraints", "description": "Connects the identified material to documented hazards and permitted uses.", "rationale": "Biological activity, supplier grade and jurisdiction must inform handling decisions without treating a registry identifier as approval.", "layers": [ { "id": "hazards-and-exposure", "name": "Hazards and exposure", "description": "Captures applicable safety classifications and evidence for exposure controls.", "findings": [ { "id": "documented-hazard-basis", "name": "Documented hazard basis", "description": "Hazard classification and exposure controls must be tied to a current source covering the actual material.", "questions": [ { "text": "Which current safety data sheet or authoritative classification covers this fluspirilene material and jurisdiction?", "kind": "provenance", "id": "documented-hazard-basis-q01" }, { "text": "What exposure limits or containment criteria are documented, and what controls follow for powder or solution handling?", "kind": "action", "id": "documented-hazard-basis-q02" } ] } ] }, { "id": "regulatory-use-boundary", "name": "Regulatory use boundary", "description": "Separates chemical identification from authorization of a product or activity.", "findings": [ { "id": "jurisdiction-specific-use", "name": "Jurisdiction-specific use evidence", "description": "Substance identifiers support record matching; pharmaceutical authorization requires separate dated, jurisdiction-specific evidence.", "questions": [ { "text": "Which jurisdiction, date and authoritative record govern the proposed procurement, research or pharmaceutical use?", "kind": "provenance", "id": "jurisdiction-specific-use-q01" }, { "text": "Does the cited permission apply to fluspirilene material, a particular medicinal product or a licensed activity?", "kind": "boundary", "id": "jurisdiction-specific-use-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall-based information; no sources were consulted.", "Verify current product authorizations and prescribing information before relying on clinical or regional details.", "Purity specifications, solid forms, solubility, thermal constants and occupational hazard classifications require source checking." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "fluspirilene", "note": "Names the active substance rather than a particular medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "1841-19-6", "note": "Identifier for fluspirilene." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "N05AG01", "note": "Classifies fluspirilene among diphenylbutylpiperidine antipsychotics." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active ingredient in long-acting intramuscular antipsychotic suspensions used for maintenance treatment of schizophrenia." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "Approximately 475.58", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Can cause extrapyramidal adverse effects, including parkinsonism, akathisia and dystonia.", "Prolonged exposure can cause tardive dyskinesia.", "Can cause hyperprolactinaemia.", "Can cause neuroleptic malignant syndrome, a rare but potentially fatal reaction.", "Long-acting administration can prolong adverse effects after treatment is stopped." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorization, availability and approved indications depend on the jurisdiction and medicinal product." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Pimozide", "difference": "A distinct diphenylbutylpiperidine antipsychotic with a different molecular structure, generally administered orally." }, { "name": "Penfluridol", "difference": "A distinct diphenylbutylpiperidine antipsychotic used as a long-acting oral medicine." }, { "name": "Fluspirilene injectable suspension", "difference": "A formulated medicinal product containing fluspirilene, with specified concentration, particle characteristics and excipients; it is not the substance alone." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of fluspirilene this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative fluspirilene specification establishes assay, related-substance limits and reference-standard requirements for each intended grade?", "Which solid forms are experimentally established, and what reliable melting, decomposition, solubility and stability measurements apply to each?", "What current GHS classifications and occupational exposure limits, if any, apply to fluspirilene in the relevant jurisdiction?", "Which fluspirilene medicinal products are currently authorized in the intended jurisdiction, and which claims about prolonged action depend on their formulation?", "Which primary receptor and functional studies best establish fluspirilene's activity profile, and which additional target effects remain experimental?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }